CLRB Stock Price, Cellectar Biosciences Quote, Chart

Market Summary

USD3.29-0.04

Delayed

-1.20%

CLRB Stock Price

View Fullscreen

CLRB RSI Chart

CLRB Valuation

Market Cap

117.9M

Price/Earnings (Trailing)

-2.31

Price/Sales (Trailing)

39.62

EV/EBITDA

-2.06

Price/Free Cashflow

-2.99

CLRB Price/Sales (Trailing)

CLRB Profitability

EBT Margin

-1326.48%

Return on Equity

-194.85%

Return on Assets

-118.82%

Free Cashflow Yield

-33.42%

CLRB Fundamentals

CLRB Revenue

Revenue (TTM)

2.9M

CLRB Earnings

Earnings (TTM)

-51.0M

Earnings Growth (Yr)

-151.5%

Earnings Growth (Qtr)

-189.74%

Breaking Down CLRB Revenue

Last 7 days

7.2%

Last 30 days

2.5%

Last 90 days

-4.6%

Trailing 12 Months

120.8%

How does CLRB drawdown profile look like?

CLRB Financial Health

Current Ratio

2.54

Debt/Equity

0.15

Debt/Cashflow

-10.15

CLRB Investor Care

Shares Dilution (1Y)

268.04%

Diluted EPS (TTM)

-3.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2015	3.8M	3.5M	3.2M	2.9M
2014	4.8M	4.5M	4.3M	4.1M
2013	0	0	0	5.0M
2011	1.2M	2.1M	3.1M	4.0M
2010	0	0	0	200.0K
2009	0	0	0	63.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cellectar Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 08, 2023	shustov andrei	acquired	-	-	47,856	senior vice president, medical
Dec 08, 2023	lea darrell shane	acquired	-	-	39,599	chief commercial officer
Dec 08, 2023	kolean chad j	acquired	-	-	42,554	chief financial officer
Dec 08, 2023	longcor jarrod	acquired	-	-	42,927	chief operating officer
Dec 08, 2023	caruso james v	acquired	-	-	40,596	president and ceo
Sep 14, 2021	swirsky douglas j	bought	26,000	1.04	25,000	-
Sep 03, 2021	driscoll frederick w	bought	20,244	1.0426	19,417	-
Mar 04, 2021	caruso james v	bought	8,658	1.6978	5,100	president and ceo
Dec 28, 2020	elefant dov	bought	9,999	1.35	7,407	chief financial officer
Dec 28, 2020	longcor jarrod	bought	40,000	1.35	29,630	chief business officer

Which funds bought or sold CLRB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	236,492	236,492	-%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-30.65	-26,368	7,455,830	0.43%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	new	-	80,519	80,519	-%
May 15, 2024	Royal Bank of Canada	new	-	10,000	10,000	-%
May 15, 2024	CITADEL ADVISORS LLC	added	70.55	277,253	468,402	-%
May 15, 2024	STATE STREET CORP	added	570	376,020	419,548	-%
May 15, 2024	MORGAN STANLEY	added	41.15	42,874	84,579	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	121,112	77,144	77,188	-%
May 15, 2024	ADAR1 Capital Management, LLC	reduced	-53.37	-1,259,970	2,557,310	0.58%
May 15, 2024	Hudson Bay Capital Management LP	new	-	597,000	597,000	-%

Are Funds Buying or Selling CLRB?

Are funds buying CLRB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CLRB

No. of Funds

Unveiling Cellectar Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	rosalind advisors, inc.	9.9%	3,305,936	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	9.9%	3,229,903	SC 13G
Feb 14, 2024	rosalind advisors, inc.	9.9%	1,488,400	SC 13G/A
Feb 14, 2024	lincoln park capital fund, llc	676%	1,307,049	SC 13G/A
Feb 14, 2024	lytton laurence w	9.99%	3,280,178	SC 13G/A
Feb 07, 2024	hirschman orin	8.7%	2,662,324	SC 13G/A
Jan 31, 2024	adar1 partners, lp	6.21%	1,824,063	SC 13G
Dec 07, 2023	lytton laurence w	9.99%	1,885,073	SC 13G
Dec 05, 2023	hirschman orin	9.9%	1,915,220	SC 13G
Feb 14, 2023	rosalind advisors, inc.	9.9%	986,293	SC 13G/A

Recent SEC filings of Cellectar Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	DEFR14A	DEFR14A
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 25, 2024	SC 13G/A	Major Ownership Report
Apr 01, 2024	10-K/A	Annual Report
Mar 27, 2024	8-K	Current Report
Mar 27, 2024	10-K	Annual Report

Peers (Alternatives to Cellectar Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Cellectar Biosciences Inc News

Latest updates

Cellectar Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2011Q4	2011Q3	2011Q2	2011Q1	2010Q4	2009Q4
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	44,479	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	255.3%	43.00	12.00	22.00	7.00	15.00	22.00	19.00	26.00	32.00	37.00	42.00	48.00	55.00	59.00	21.00	24.00	9.00	12.00	16.00	19.00	13.00
Current Assets	295.7%	41.00	10.00	20.00	6.00	14.00	21.00	19.00	25.00	31.00	37.00	41.00	47.00	54.00	58.00	20.00	23.00	8.00	11.00	15.00	18.00	11.00
Cash Equivalents	318.5%	40.00	10.00	19.00	5.00	13.00	20.00	18.00	25.00	31.00	36.00	40.00	47.00	54.00	57.00	19.00	22.00	7.00	11.00	13.00	17.00	10.00
Net PPE	-6.1%	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00
Liabilities	24.6%	17.00	13.00	17.00	7.00	8.00	6.00	7.00	6.00	5.00	4.00	3.00	4.00	5.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00
Current Liabilities	25.7%	16.00	13.00	16.00	6.00	7.00	6.00	7.00	6.00	5.00	4.00	3.00	4.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	2.00
Shareholder's Equity	2029.6%	26.00	-1.36	-	-	7.00	16.00	13.00	20.00	27.00	33.00	39.00	44.00	50.00	55.00	16.00	20.00	5.00	9.00	12.00	16.00	10.00
Retained Earnings	-9.9%	-239	-217	-210	-196	-	-179	-172	-164	-	-150	-144	-139	-133	-126	-123	-119	-115	-111	-108	-104	-101
Additional Paid-In Capital	18.1%	248	210	195	194	194	194	184	183	183	183	182	175	171	162	138	138	120	120	119	119	109
Shares Outstanding	55.5%	32.00	21.00	10.00	10.00	10.00	9.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	19.00	-	-	-	24.00	-	-	-	65.00	-	-	-	32.00	-	-	-	20.00	-

Cashflow (Last 12 Months)

(In )

Cashflow (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-39.2%	-13,361,641	-9,595,700	-8,067,885	-7,529,719	-7,183,670	-7,411,763	-7,013,177	-5,757,578	-5,039,783	-4,511,012	-6,429,065	-6,876,182	-4,752,579	-3,868,709	-3,502,063	-3,049,901	-3,512,070	-2,681,165	-3,544,358	-2,652,910	-2,815,275
Share Based Compensation	-58.1%	454,363	1,084,447	497,878	419,757	408,206	361,447	367,759	419,953	303,805	377,848	421,161	200,617	124,564	114,460	116,292	92,643	144,146	207,892	149,774	301,471	207,654
Cashflow From Investing	91.9%	-21,633	-266,756	-	-	-	-117,856	-7,066	-70,979	-30,070	-129,739	-4,063	-	-	-17,210	-	-34,590	-10,553	-5,725	-3,093	-9,482	-6,242
Cashflow From Financing	9843.2%	43,849,467	441,001	22,498,638	-	3.00	-	-	-	-	-1.00	-	34,874	1,213,924	42,209,352	-106,196	18,442,595	-	-	-568	9,023,735	-811

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CLRB Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
COSTS AND EXPENSES:
Research and development	$ 7,377,940	$ 6,654,094
General and administrative	4,623,546	2,051,207
Total costs and expenses	12,001,486	8,705,301
LOSS FROM OPERATIONS	(12,001,486)	(8,705,301)
OTHER (LOSS) INCOME:
Loss on valuation of warrants	(9,900,000)
Interest income, net	319,849	124,034
Total other (loss) income, net	(9,580,151)	124,034
NET LOSS	$ (21,581,637)	$ (8,581,267)
BASIC NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE	$ (0.74)	$ (0.76)
DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE	$ (0.74)	$ (0.76)
SHARES USED IN COMPUTING BASIC NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE	29,346,679	11,261,217
SHARES USED IN COMPUTING DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE	29,346,679	11,261,217

CLRB Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 40,031,181	$ 9,564,988
Prepaid expenses and other current assets	1,337,184	888,225
Total current assets	41,368,365	10,453,213
Fixed assets, net	1,023,447	1,090,304
Right-of-use asset, net	486,847	502,283
Long-term assets	23,566	23,566
Other assets	6,214	6,214
TOTAL ASSETS	42,908,439	12,075,580
CURRENT LIABILITIES:
Accounts payable and accrued liabilities	7,393,950	9,178,645
Warrant liability	8,800,000	3,700,000
Lease liability	73,994	58,979
Total current liabilities	16,267,944	12,937,624
Long-term lease liability, net of current portion	474,349	494,003
TOTAL LIABILITIES	16,742,293	13,431,627
COMMITMENTS AND CONTINGENCIES (Note 7)
STOCKHOLDERS' EQUITY (DEFICIT):
Common stock, $0.00001 par value; 170,000,000 shares authorized; 33,164,466 and 20,744,110 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	332	207
Additional paid-in capital	248,151,681	210,066,630
Accumulated deficit	(239,064,176)	(217,482,539)
Total stockholders' equity (deficit)	26,166,146	(1,356,047)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	42,908,439	12,075,580
Series D preferred stock
STOCKHOLDERS' EQUITY (DEFICIT):
Preferred stock	1,382,023	1,382,023
Series E-2 Preferred Stock
STOCKHOLDERS' EQUITY (DEFICIT):
Preferred stock	3,474,286	$ 4,677,632
Series E-3 preferred stock
STOCKHOLDERS' EQUITY (DEFICIT):
Preferred stock	$ 12,222,000

About Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

CEO	Mr. James V. Caruso
WEBSITE	cellectar.com
INDUSTRY	Biotechnology
EMPLOYEES	15

Cellectar Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Cellectar Biosciences Inc? What does CLRB stand for in stocks?

CLRB is the stock ticker symbol of Cellectar Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cellectar Biosciences Inc (CLRB)?

As of Fri May 17 2024, market cap of Cellectar Biosciences Inc is 117.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLRB stock?

You can check CLRB's fair value in chart for subscribers.

What is the fair value of CLRB stock?

You can check CLRB's fair value in chart for subscribers. The fair value of Cellectar Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cellectar Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CLRB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cellectar Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether CLRB is over valued or under valued. Whether Cellectar Biosciences Inc is cheap or expensive depends on the assumptions which impact Cellectar Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLRB.

What is Cellectar Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CLRB's PE ratio (Price to Earnings) is -2.31 and Price to Sales (PS) ratio is 39.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLRB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cellectar Biosciences Inc's stock?

In the past 10 years, Cellectar Biosciences Inc has provided -0.413 (multiply by 100 for percentage) rate of return.